Core binding factor acute myelogenous leukemia-2021 treatment algorithm.
Algorithms
Anthracyclines
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Chromosome Inversion
Chromosomes, Human
/ genetics
Core Binding Factors
/ blood
Cytarabine
/ therapeutic use
Disease-Free Survival
Humans
Leukemia, Myeloid, Acute
/ blood
Neoplasm Proteins
/ blood
Neoplasm, Residual
Translocation, Genetic
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
16 06 2021
16 06 2021
Historique:
received:
29
01
2021
accepted:
24
05
2021
revised:
29
03
2021
entrez:
17
6
2021
pubmed:
18
6
2021
medline:
1
2
2022
Statut:
epublish
Résumé
Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered good-risk AML in the context of cytarabine based intensive chemotherapy. Still, outcome can be improved significantly through the effective implementation of available therapeutic measures and appropriate disease monitoring. The incorporation of gemtuzumab ozogamicin into frontline therapy should be standard. Cytarabine based induction/consolidation regimen may be combined with anthracycline (3 + 7 standard) or antimetabolite, fludarabine. Serial quantitative polymerase chain reaction (QPCR) monitoring of unique fusion transcripts allows monitoring for measurable residual disease clearance; this allows for better prognostication and well as treatment modifications.
Identifiants
pubmed: 34135311
doi: 10.1038/s41408-021-00503-6
pii: 10.1038/s41408-021-00503-6
pmc: PMC8209225
doi:
Substances chimiques
Anthracyclines
0
Core Binding Factors
0
Neoplasm Proteins
0
Cytarabine
04079A1RDZ
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
114Références
Blood. 2010 Mar 25;115(12):2372-9
pubmed: 20056794
Leukemia. 2001 Jul;15(7):1072-80
pubmed: 11455976
Am J Hematol. 2014 Oct;89(10):964-8
pubmed: 24990142
J Clin Oncol. 2006 Aug 20;24(24):3904-11
pubmed: 16921041
Leukemia. 2018 Dec;32(12):2698-2701
pubmed: 29884905
J Clin Oncol. 2004 Sep 15;22(18):3741-50
pubmed: 15289486
Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e19-e25
pubmed: 29107583
Leukemia. 2013 Sep;27(9):1891-901
pubmed: 23783394
Blood. 2014 Aug 21;124(8):1312-9
pubmed: 25006122
Blood. 2002 Dec 15;100(13):4325-36
pubmed: 12393746
Cancer. 1995 Feb 1;75(3):821-5
pubmed: 7828132
Br J Haematol. 1995 Sep;91(1):104-8
pubmed: 7577615
Cancer. 2009 Jul 15;115(14):3217-21
pubmed: 19441109
Leukemia. 2018 Jul;32(7):1621-1630
pubmed: 29720733
Cancer. 2008 Dec 1;113(11):3181-5
pubmed: 18932257
J Clin Oncol. 2005 Aug 20;23(24):5705-17
pubmed: 16110030
Leukemia. 2016 Feb;30(2):501-4
pubmed: 26139325
J Clin Oncol. 2004 Mar 15;22(6):1087-94
pubmed: 15020610
Blood. 2013 May 16;121(20):4056-62
pubmed: 23535063
J Clin Oncol. 2011 Feb 1;29(4):369-77
pubmed: 21172891
Leukemia. 2003 Aug;17(8):1521-8
pubmed: 12886238
Leukemia. 2018 Oct;32(10):2270-2274
pubmed: 29568097
Br J Haematol. 2006 Oct;135(2):165-73
pubmed: 16939487
J Clin Oncol. 2009 Oct 1;27(28):4747-53
pubmed: 19720919
Best Pract Res Clin Haematol. 2001 Mar;14(1):19-47
pubmed: 11355922
Blood. 2019 Mar 7;133(10):1140-1151
pubmed: 30610028
Blood. 2003 Jul 15;102(2):462-9
pubmed: 12649129
Blood. 2016 May 19;127(20):2451-9
pubmed: 26980726
Blood. 1998 Oct 1;92(7):2322-33
pubmed: 9746770
Nat Genet. 2016 Dec;48(12):1551-1556
pubmed: 27798625
Blood. 2010 Jul 22;116(3):354-65
pubmed: 20385793
Blood. 2012 Oct 4;120(14):2826-35
pubmed: 22875911
Am J Hematol. 2020 Jul;95(7):799-808
pubmed: 32249963
Blood. 2018 Jul 12;132(2):187-196
pubmed: 29692343
Blood. 2003 Jan 1;101(1):270-7
pubmed: 12393465
N Engl J Med. 2009 Sep 24;361(13):1249-59
pubmed: 19776406
Blood Adv. 2020 Feb 25;4(4):696-705
pubmed: 32092139
J Clin Oncol. 1999 Dec;17(12):3767-75
pubmed: 10577848
J Clin Oncol. 2013 Sep 20;31(27):3360-8
pubmed: 23940227
Blood. 2013 Mar 21;121(12):2213-23
pubmed: 23321257
Leukemia. 2007 Jun;21(6):1177-82
pubmed: 17377588
Nat Rev Cancer. 2002 Jul;2(7):502-13
pubmed: 12094236
Am J Clin Pathol. 2016 Jun;145(6):769-77
pubmed: 27298396
J Clin Oncol. 1993 Jan;11(1):116-24
pubmed: 8418222
Mol Cell. 2021 Feb 4;81(3):530-545.e5
pubmed: 33382982
Lancet Oncol. 2014 Aug;15(9):986-96
pubmed: 25008258
Am J Hematol. 2017 Sep;92(9):845-850
pubmed: 28494506